Clinical and laboratory features heralding the appearance of thymoma: extended abstract
Extended Abstract

Clinical and laboratory features heralding the appearance of thymoma: extended abstract

Mohammad Reza Ashraghi, M. Isabel Leite

Nuffield Department of Clinical Neurosciences, University of Oxford and Oxford University Hospitals NHS Foundation Trust, Oxford, UK

Correspondence to: Dr Mohammad Reza Ashraghi, BSc, MBBS, MRCP. Nuffield Department of Clinical Neurosciences, Level 6, West Wing, John Radcliffe Hospital, Oxford OX3 9DU, UK. Email:

Received: 09 December 2021; Accepted: 08 April 2022; Published: 25 June 2022.

doi: 10.21037/med-21-59


Thymic malignancies are tumours of the anterior mediastinum. While rare, their association with a variety of paraneoplastic disorders has led to them being extensively studied. The most common and best understood of these associations is with Myasthenia gravis (MG). MG is an autoimmune disease of the neuromuscular junction causing weakness of the skeletal muscle. While several antibodies have been identified in association with MG, only those against acetylcholine receptors (AChR) and muscle specific kinase (MuSK) are routinely used clinically, and only AChR antibodies have an association with thymic pathology. Overall, 15% of patients with MG have thymoma, while up to 50% of patients with thymoma have MG (1). While there is no definitive marker of the presence of a thymoma in MG, there are several clinical and laboratory indicators which should raise suspicion. Here, we discuss some of these indicators.

MG and thymoma

Clinical features of MG

MG associated with thymoma can present with the full spectrum of clinical features seen in MG without thymoma. However, certain characteristics are more common. While MG incidence has a bimodal distribution and the risk of thymoma overall increases with age, peaking in the seventh decade, the peak incidence of MG with thymoma is in the fourth to sixth decades of life (2,3). MG in association with thymoma is more likely to be severe, with increased frequency of early bulbar, respiratory and neck muscle involvement. Limbs can be relatively spared (4). It is also important to a new or recurrent thymoma in patients who become more symptomatic or treatment resistant without a clear cause, having been previously stable.

Laboratory features of MG

The presence of anti-titin and anti-ryanodine receptor (anti-RyR) antibodies are associated with the presence of thymoma in some MG patients. These antibodies are not pathogenic, or specific for MG. Anti-titin antibodies are present in approximately 30% of all MG patients with AChR antibodies, but this number increases to as high as 90% of patients with thymoma and MG (5-7). However, approximately 50% of patients with late onset MG (LOMG) without thymoma also have anti-titin antibodies, with the proportion of anti-titin positive patients increasing linearly from 40% in the sixth decade to 88% in the ninth decade of life (5). Overall, anti-titin antibodies have a 90% positive predictive value (PPV) and 95% negative predictive value (NPV) in early onset MG (EOMG) and 71% PPV and 55% NPV in LOMG. Therefore, the presence of anti-titin antibodies as an indicator of possible underlying thymoma can be of use in EOMG and should precipitate careful investigation for a thymoma (5). Similar to anti-titin antibodies are anti-RyR antibodies. These can be present in 50–70% of patients with AChR antibodies and thymoma and up to 20% LOMG patients without thymoma. As a result, their use is primarily in EOMG as well (1,7-10). It is notable that anti-RyR antibodies are associated with increased frequency of bulbar, neck weakness at disease onset, while anti-titin antibodies are associated with more frequent respiratory involvement, though bulbar involvement is also more common (5,11,12). This is in keeping with the clinical findings observed in MG with thymoma. At present, anti-titin antibody testing is more available than anti-RyR and therefore is used more frequently in the clinical setting.

Metastases and other paraneoplastic syndromes

It is important for a clinician to be aware of the spectrum of symptoms thymoma can cause beyond MG. Local invasion of the lung and pleura can cause chest pain and breathlessness, while superior vena cava obstruction is well recognised. Rarely, distant metastases can spread to locations such as liver and adrenal glands and should be considered (13). Furthermore, many paraneoplastic syndromes can be seen with thymoma and up to 15% of patients with thymoma will develop a paraneoplastic syndrome other than MG. Therefore, patients with MG who display clinical features suggestive of other paraneoplastic syndromes should be aggressively investigated. These may include anaemia, hypogammaglobulinaemia, alopecia, lichen planus and many others (14,15).

Infection and thymoma

Infections are commonly seen in patients with MG. Often, these can be attributed directly to their MG, such as with aspiration pneumonia or due to immunosuppression. However, in the event of recurrent infections or opportunistic infections, one must consider other possibilities that could relate to an underlying thymoma.

Good syndrome

One well recognised cause of such infections is Good syndrome. A paraneoplastic disorder that results in hypogammaglobulinaemia, low or absent B cells in peripheral blood and, in some cases, changes in T-cell mediated immunity as well. However, one must exercise caution when interpreting such laboratory findings as rituximab can produce a similar effect. Infections commonly associated with Good syndrome usually affect the upper and lower respiratory tracts with bronchiectasis sometimes developing. However, a whole range of atypical infections can occur (16).

Cytokine antibodies

Many cytokine antibodies have been identified, some of which are associated with thymoma, immunodeficiency and infection (17). It is unclear which of these are pathogenic. Some appear to be associated specifically with thymoma patients who develop opportunistic infections while others do not (18). Interferon-α and interferon-ω antibodies are found to be elevated in thymoma regardless of infection, but interleukin (IL)-12 p35 and IL-17 are specifically elevated in patients with thymoma and opportunistic infections (7,18). Certain cytokine antibodies such as those against as IL-12, IL-22 and IL-17 are associated with particular infections such as chronic mucocutaneous candidiasis, while others can be associated with a range of mycobacterium, cryptococcal infections or severe bacterial infections. The presence of such infections should precipitate in-depth investigation for an underlying thymoma (14,17,19). It is likely that rather than a single cytokine antibody being responsible, various combinations of antibodies result in immunodeficiency predisposing to different infections.


In conclusion, the presence of anti-titin or anti-RyR antibodies in EOMG, or the presence of bulbar or respiratory symptoms, should raise the possibility thymoma. In addition, it is important to be aware of other associated paraneoplastic syndromes and to have a low threshold to investigate for thymoma in those with persistent or opportunistic infections.


Funding: None.


Provenance and Peer Review: This article was commissioned by the Guest Editors (Malgorzata Szolkowska, Mirella Marino, Katarzyna Blasinska, Magdalena Knetki-Wroblewska, and Giuseppe Cardillo) for “The Series Dedicated to the 11th International Thymic Malignancy Interest Group Annual Meeting (Virtual ITMIG 2021)” published in Mediastinum. The article has undergone external peer review.

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at “The Series Dedicated to the 11th International Thymic Malignancy Interest Group Annual Meeting (Virtual ITMIG 2021)” was commissioned by the editorial office without any funding or sponsorship. The authors have no other conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See:


  1. Romi F, Hong Y, Gilhus NE. Pathophysiology and immunological profile of myasthenia gravis and its subgroups. Curr Opin Immunol 2017;49:9-13. [Crossref] [PubMed]
  2. Iorio R, Spagni G, Evoli A. Paraneoplastic neurological syndromes associated with mediastinal tumors. Mediastinum 2018;2:8. [Crossref]
  3. Engels EA. Epidemiology of thymoma and associated malignancies. J Thorac Oncol 2010;5:S260-5. [Crossref] [PubMed]
  4. Romi F. Thymoma in myasthenia gravis: from diagnosis to treatment. Autoimmune Dis 2011;2011:474512. [Crossref] [PubMed]
  5. Szczudlik P, Szyluk B, Lipowska M, et al. Antititin antibody in early- and late-onset myasthenia gravis. Acta Neurol Scand 2014;130:229-33. [Crossref] [PubMed]
  6. Romi F, Skeie GO, Aarli JA, et al. Muscle autoantibodies in subgroups of myasthenia gravis patients. J Neurol 2000;247:369-75. [Crossref] [PubMed]
  7. Marx A, Hohenberger P, Hoffmann H, et al. The autoimmune regulator AIRE in thymoma biology: autoimmunity and beyond. J Thorac Oncol 2010;5:S266-72. [Crossref] [PubMed]
  8. Romi F, Skeie GO, Gilhus NE, et al. Striational antibodies in myasthenia gravis: reactivity and possible clinical significance. Arch Neurol 2005;62:442-6. [Crossref] [PubMed]
  9. Skeie GO, Lunde PK, Sejersted OM, et al. Autoimmunity against the ryanodine receptor in myasthenia gravis. Acta Physiol Scand 2001;171:379-84. [Crossref] [PubMed]
  10. Mygland A, Aarli JA, Matre R, et al. Ryanodine receptor antibodies related to severity of thymoma associated myasthenia gravis. J Neurol Neurosurg Psychiatry 1994;57:843-6. [Crossref] [PubMed]
  11. Romi F, Aarli JA, Gilhus NE. Myasthenia gravis patients with ryanodine receptor antibodies have distinctive clinical features. Eur J Neurol 2007;14:617-20. [Crossref] [PubMed]
  12. Romi F, Skeie GO, Aarli JA, et al. The severity of myasthenia gravis correlates with the serum concentration of titin and ryanodine receptor antibodies. Arch Neurol 2000;57:1596-600. [Crossref] [PubMed]
  13. Khandelwal A, Sholl LM, Araki T, et al. Patterns of metastasis and recurrence in thymic epithelial tumours: longitudinal imaging review in correlation with histological subtypes. Clin Radiol 2016;71:1010-7. [Crossref] [PubMed]
  14. Santos E, Silva AM, Stroebel P, et al. Signs heralding appearance of thymomas after extended thymectomy for myasthenia gravis. Neurol Clin Pract 2019;9:48-52. [Crossref] [PubMed]
  15. Zhao J, Bhatnagar V, Ding L, et al. A systematic review of paraneoplastic syndromes associated with thymoma: Treatment modalities, recurrence, and outcomes in resected cases. J Thorac Cardiovasc Surg 2020;160:306-314.e14. [Crossref] [PubMed]
  16. Tarr PE, Sneller MC, Mechanic LJ, et al. Infections in patients with immunodeficiency with thymoma (Good syndrome). Report of 5 cases and review of the literature. Medicine (Baltimore) 2001;80:123-33. [Crossref] [PubMed]
  17. Barcenas-Morales G, Cortes-Acevedo P, Doffinger R. Anticytokine autoantibodies leading to infection: early recognition, diagnosis and treatment options. Curr Opin Infect Dis 2019;32:330-6. [Crossref] [PubMed]
  18. Burbelo PD, Browne SK, Sampaio EP, et al. Anti-cytokine autoantibodies are associated with opportunistic infection in patients with thymic neoplasia. Blood 2010;116:4848-58. [Crossref] [PubMed]
  19. Kisand K, Lilic D, Casanova JL, et al. Mucocutaneous candidiasis and autoimmunity against cytokines in APECED and thymoma patients: clinical and pathogenetic implications. Eur J Immunol 2011;41:1517-27. [Crossref] [PubMed]
doi: 10.21037/med-21-59
Cite this article as: Ashraghi MR, Leite MI. Clinical and laboratory features heralding the appearance of thymoma: extended abstract. Mediastinum 2022;6:19.

Download Citation